AAV Vector Biology
AAV can transduce a broad set of cell types, including hepatocytes, cardiomyocytes, skeletal muscle, neurons, glia, retinal cells, and some epithelial cells. Selecting the right vector requires considering capsid, cell type, species, route of administration, and promoter together. Capsid determines where the vector is delivered and which cells are easier to transduce; the promoter determines where the transgene is expressed once inside.
Explore Cell TypesDiscuss Your Target CellTarget Cells
AAV is widely used across many tissues, but the efficiency of any given serotype is highly cell- and context-dependent.
| Cell / tissue | Commonly used capsids | Practical notes |
|---|---|---|
| Hepatocytes (liver) | AAV8 and others | Highly studied target for systemic delivery and inherited liver disease research; tropism varies by serotype. |
| Cardiomyocytes (heart) | AAV9 mainly | Used for cardiovascular and genetic cardiomyopathy research; efficiency depends on species, route, and dose. |
| Skeletal muscle | AAV6, AAV8, AAV9, engineered capsids | Common target for muscle-related disease; no single serotype suits all muscle contexts. |
| Neurons (CNS) | AAV2, AAV9, engineered capsids | Delivered by local injection, intracerebroventricular, or intrathecal routes; tropism varies by brain region. |
| Glial cells | Serotype- and promoter-dependent | Selective glial expression usually requires cell-type-preferring promoters. |
| Retinal cells | AAV2, AAV5, AAV8 | Targets photoreceptors, RPE, and other retinal cells; efficiency varies by cell and injection site. |
| Lung, pancreas, kidney, intestine | Serotype-dependent | Less established than liver, muscle, CNS, and retina; efficiency is more variable and should be verified empirically. |
Serotype Reference
The table summarizes commonly reported tropism for well-studied serotypes. Reported tropism varies by species, route, and construct, so it should be treated as a starting point rather than a guarantee.
| Serotype | Commonly reported tropism | Typical notes |
|---|---|---|
| AAV1 | Muscle, heart, retina | Broad muscle and cardiac transduction. |
| AAV2 | Neurons, retina, liver (moderate) | First characterized; local CNS and ocular use. |
| AAV3 | Liver, cochlea | Human-derived serotype; moderate hepatic tropism. |
| AAV4 | Retinal pigment epithelium, CNS | Commonly used for RPE-directed delivery. |
| AAV5 | Retina, lung, CNS | Distinct transduction pattern; ocular applications. |
| AAV6 | Muscle, heart, lung | Strong muscle and cardiac transduction. |
| AAV7 | Muscle, retina, CNS | Rhesus-derived; efficient muscle transduction. |
| AAV8 | Liver, muscle, retina, pancreas | Widely used for liver-directed gene therapy. |
| AAV9 | Heart, muscle, lung, CNS (BBB crossing) | Broad systemic tropism; crosses the blood–brain barrier. |
| AAVrh10 | CNS, liver, muscle | Rhesus-derived; commonly used for CNS delivery. |
Reported tropism is context-dependent and should be verified empirically in the intended target cell, species, and route.
Why Results Differ
The same AAV can behave differently in different cells because transduction is controlled by multiple interacting variables.
Different capsids interact with different cell-surface receptors and co-factors, producing distinct tissue and cell tropism. A property of one serotype cannot be assumed for another.
Entry, trafficking, and processing depend on receptors and co-factors that vary between cell types, so the same capsid can transduce one cell efficiently and another poorly.
In vitro delivery, local injection, intravenous, and intracerebroventricular administration change which cells the vector can reach, and therefore the observed outcome.
Species, origin, and culture state can shift receptor expression, intracellular trafficking, or expression, changing results even for a fixed construct.
The promoter determines whether and where the transgene is expressed after entry. Tissue- or cell-preferring promoters improve expression selectivity.
Administration Routes
The same capsid can reach different cells depending on how it is administered.
Intravenous administration distributes AAV broadly and favors the liver, heart, and muscle depending on the capsid (for example, AAV8 for liver and AAV9 for heart and muscle).
Direct stereotactic injection delivers AAV to specific brain regions for focal neuronal transduction, commonly with AAV2, AAV9, or engineered capsids.
Cerebrospinal-fluid routes deliver AAV broadly through the CNS, reaching neurons and glia without focal surgery.
Subretinal injection targets photoreceptors and retinal pigment epithelium, while intravitreal injection targets inner retinal cells, each with distinct serotype preferences.
Key Distinctions
Most confusion in AAV tropism comes from conflating related but distinct ideas.
AAV must bind, internalize, traffic, escape the endosome, enter the nucleus, uncoat, and express before a readout appears. Cell entry does not guarantee efficient transduction or high-level transgene expression.
The capsid controls where the vector is delivered and which cells are easier to transduce; the promoter controls where the transgene is expressed once inside. Both must be chosen together.
A capsid may favor a tissue that still contains many cell types. Restricting expression to one cell type usually requires a cell-type-preferring promoter in addition to the capsid.
Different laboratories, cell sources, and vector lots can yield different results, so empirical comparison in the target cell remains the most reliable selection method.
Achieving Specificity
Because tissue tropism is not cell specificity, targeting specific cell types usually requires combining capsid engineering with transcriptional and post-transcriptional control.
Peptide insertion, rational mutation, and directed evolution can shift capsid tropism toward a desired cell type or away from off-target tissues.
Cell-preferring promoters (for example, synapsin for neurons) restrict transgene expression even when the capsid transduces multiple cell types.
miRNA target sites in the 3′ UTR can silence expression in cells that express the corresponding miRNA, adding post-transcriptional control.
Combining capsid engineering, cell-preferring promoters, and miRNA detargeting provides the strongest route to cell-type-specific expression.
In Vitro Selection
For in vitro experiments, a structured approach reduces trial-and-error and makes the final choice evidence-based.
Specify the cell line or primary cell, such as hepatocytes, neurons, cardiomyocytes, or fibroblasts.
Choose candidate serotypes or engineered capsids based on literature and prior experience.
Use a broad promoter for validation, or a cell-preferring promoter for selective expression.
Include negative controls, empty vector, or reporter controls to separate delivery from transgene effect.
Compare candidate AAVs side by side in the target cell rather than relying on theoretical tropism.
Refine capsid, promoter, dose, and route based on the actual transduction result.
Project Support
Creative Biolabs provides AAV design, capsid engineering, and targeting capabilities that can be scoped around your target cell, tissue, and expression requirements.
Build a coherent capsid and cassette strategy for your target tissue and indication.
Configure the expression cassette and promoter for selective or high-level expression.
Engineer capsids to shift tropism toward your intended cell type.
Apply targeting strategies to improve delivery selectivity to your tissue of interest.
Use cell-preferring promoters to restrict expression to the intended cell type.
Access the full AAV development and characterization capability set.
References
FAQ
Share your target cell or tissue, species, route, and expression requirements. Creative Biolabs can help select a capsid and promoter strategy and validate transduction empirically.
Inquiry NowTell us about your project, and our experts will get back to you with a customized quote and proposal.
